# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen...
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical mode...
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimul...
Surrozen (NASDAQ:SRZN) reported quarterly losses of $(4.24) per share which beat the analyst consensus estimate of $(4.25) by 0...
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expect...
Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Pha...